{
  "generated": "2025-10-24T08:19:06.979710+00:00",
  "policy_fingerprint": "0xbe3a798944b1c64b",
  "source_evidence": "entries/metabolic/berberine-meta-glu01/metabolic/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "META-GLU01_01",
      "year": 2015,
      "design": "randomized controlled trial",
      "journal": "metabolic_journal",
      "outcome": "glucose_control",
      "population": "Adults with glucose control concerns",
      "adverse_events": "Transient headache",
      "doi": "10.1234/berberine-meta-glu01-01",
      "url": "https://doi.org/10.1234/berberine-meta-glu01-01",
      "citation": "META-GLU01_01 (2015); Journal: metabolic_journal; Design: randomized controlled trial; Population: Adults with glucose control concerns; Outcome: glucose_control; DOI: 10.1234/berberine-meta-glu01-01; Adverse Events: Transient headache."
    },
    {
      "study_id": "META-GLU01_02",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "metabolic_journal",
      "outcome": "glucose_control",
      "population": "Adults with glucose control concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/berberine-meta-glu01-02",
      "url": "https://doi.org/10.1234/berberine-meta-glu01-02",
      "citation": "META-GLU01_02 (2016); Journal: metabolic_journal; Design: randomized controlled trial; Population: Adults with glucose control concerns; Outcome: glucose_control; DOI: 10.1234/berberine-meta-glu01-02; Adverse Events: None reported."
    },
    {
      "study_id": "META-GLU01_03",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "metabolic_journal",
      "outcome": "glucose_control",
      "population": "Adults with glucose control concerns",
      "adverse_events": "Transient headache",
      "doi": "10.1234/berberine-meta-glu01-03",
      "url": "https://doi.org/10.1234/berberine-meta-glu01-03",
      "citation": "META-GLU01_03 (2017); Journal: metabolic_journal; Design: randomized controlled trial; Population: Adults with glucose control concerns; Outcome: glucose_control; DOI: 10.1234/berberine-meta-glu01-03; Adverse Events: Transient headache."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/berberine-meta-glu01-01",
      "study_ids": [
        "META-GLU01_01"
      ],
      "primary_study_id": "META-GLU01_01",
      "url": "https://doi.org/10.1234/berberine-meta-glu01-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/berberine-meta-glu01-02",
      "study_ids": [
        "META-GLU01_02"
      ],
      "primary_study_id": "META-GLU01_02",
      "url": "https://doi.org/10.1234/berberine-meta-glu01-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/berberine-meta-glu01-03",
      "study_ids": [
        "META-GLU01_03"
      ],
      "primary_study_id": "META-GLU01_03",
      "url": "https://doi.org/10.1234/berberine-meta-glu01-03"
    }
  ],
  "manifest_hash": "sha256:634a2985f6c9dfdde24a39b6f987f54d821c53d799e4977d9f272da9b0befcb3"
}
